Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
BOSTON, MASSACHUSETTS, May 29, 2019 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTC: BIXT), a developmental stage biotechnology company with a pipeline of anti-necrosis drugs designed to treat hypoxia by...
-
Future use of the MDX Viewer likely to start in operating rooms, clinical trials to measure tissue balance in stroke, and to test the viability of an organ before transplantation BOSTON,...
-
BOSTON, MASSACHUSETTS, May 06, 2019 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTC: BIXT), a developmental stage biotechnology company developing a pipeline of anti-necrosis drugs designed to treat...
-
BOSTON, MASSACHUSETTS, April 04, 2019 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTC: BIXT), a developmental stage biotechnology company with a pipeline of anti-necrosis drugs designed to treat hypoxia by...
-
BOSTON, MASSACHUSETTS, March 18, 2019 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTC: BIXT), a developmental stage biotechnology company, with a pipeline of anti-necrosis drugs designed to treat hypoxia...
-
Newly Developed Molecule Potentially Allows Oxygen Flow to the Brain BOSTON, MASSACHUSETTS, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Bioxytran Inc. (BIXT). Dr. David Platt, CEO of newly formed...
-
Company Formerly Known as U.S. Rare Earth Minerals, Inc. Focusing on First-In-Class Ischemic Stroke Treatment BOSTON, Nov. 12, 2018 (GLOBE NEWSWIRE) -- U.S. Rare Earth Minerals, Inc. today...